Arcutis Biotherapeutics（纳斯达克股票代码：ARQT）报告季度每股亏损$(0.09)，比分析师普遍预期的$(0.24)高62.5%。与去年同期每股亏损$(0.72)相比，这一数据增加了87.5%。公司报告季度销售额为$71.400百万，超出分析师普遍预期的$60.160百万，增幅为18.68%。与去年同期销售额$13.526百万相比，这一数据增加了427.87%。

以上内容来自Benzinga Earnings专栏，原文如下：

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.24) by 62.5 percent. This is a 87.5 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $71.400 million which beat the analyst consensus estimate of $60.160 million by 18.68 percent. This is a 427.87 percent increase over sales of $13.526 million the same period last year.